Antibiotic resistance is very much in the news, which adds a timeliness to a deal between clinical product supply specialist Clinigen (CLIN) and US biotech company Theravance (THRX). Clinigen has tied up the European rights for Vibativ, a treatment for drug-resistant pneumonia resulting from an MRSA super-bug infection.
IC TIP:
Buy
at
270p
Vibativ isn't a new anti-biotic, but it can treat the side-effects of MRSA, including hospital-acquired pneumonia. For a $5m (£3.3m) upfront fee, Clinigen has acquired the EU rights to Vibativ, as well as rights for Switzerland and Norway, and will pay a royalty to Theravance of between 20 per cent and 30 per cent, depending on sales.
